Early access program for Molecular Dynamics' microarray technology gaining momentum.
This article was originally published in The Gray Sheet
Executive SummaryMOLECULAR DYNAMICS DEVELOPING TOXARRAY PRE-ARRAYED DNA TOXICOLOGY SLIDES in collaboration with Phase-I Molecular Technology, company President and CEO Jay Flatley reported at a Jan. 12 session of the Hambrecht & Quist health care conference in San Francisco. "With Phase-I, we will jointly be developing a series of pre-arrayed DNA slides called ToxArray, using their toxicology technology and then supplying that out to the pharmaceutical partners in our technology access group," Flatley said.
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.